Summary
No overall score for this company yet.
What speaks for it
- It could repay all its net debt from 0.9 years of operating profit.
- The price moves less than the market (beta 0.21).
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Today you pay 22.6 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Revenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 7.0%.
Growth in detailDoes it make money?
Where 100 JPY of revenue goes
- Cost of sales 35 JPY
- Research and development 7.8 JPY
- Sales and administration 42 JPY
- Taxes and other 7.3 JPY
- Net profit 7.5 JPY
Net profit, industry median (Medical - Devices) 6.9 JPY
Out of every 100 JPY of revenue, 7.5 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.